NCT01855711View on ClinicalTrials.gov

Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 18, 2003

Primary Completion Date

May 10, 2005

Study Completion Date

May 10, 2005

Conditions
Irritable Colon
Interventions
DRUG

GR68755 (Alosetron hydrochloride) 1 mg tablet

1 tablet (1 mg) once a day

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY